ÂÜÀòÂÒÂ×

Aris Persidis is an entrepreneur and innovator in Big Data and AI Gamification with an established 20-year track record. He is Co-Founder and President of Biovista, the Big Data/AI drug repositioning and precision medicine pioneer, ranked Top-10 worldwide in healthcare AI (Forbes; CIO Bulletin; Deep Knowledge Analytics). He has negotiated and closed relevant deals with some of the most well-known organizations in the world, including Hewlett Packard Enterprise, Pfizer, Novartis, Astellas, BiogenIdec, the FDA, and a number of Patient Advocacy Groups.

Arishas extensive operational and M&A experience. Prior to Biovista Aris was SVP, Research, and Business Development, at Upstate (acquired by Serologicals for $205MM), and VP of Business Development at Serologicals (acquired by Millipore for $1.4 Billion). Aris also worked on the establishment of and received co-founder stock in healthcare companies with significant growth and exits: Cellzome (acquired by GSK for $100 MM), Anadys (acquired by Roche for $240 MM), and RheoGene (acquired by Intrexon).

Other notables: Board appointments: Biovista, GNB (GridNewsBureau); Received the Honeywell Futurist Award while a 3rd-year undergraduate student; Served as Assistant Professor (Adjunct) and also Assistant Director, Medical Center Technology Transfer Program, at Wharton; Served as the first elected Chairperson of the Jefferson Corner Group Fund I, an angel investor group in Charlottesville, VA; Sole author of the monthly Industry Trends review column for Nature Biotechnology; Served as the first Editor-in-Chief of the journal Drug Repurposing, Rescue, and Repositioning; Published over 90 papers and book chapters; Guest lectured at Wharton, Columbia, George Washington, and the University of Auckland Business School; In early 2020, Aris was recognized as one of the world’s top-50 Futurists (Abundant World Institute – Toffler Association). Education: Aris received a First-Class B.Sc. degree in biological chemistry from Essex University, U.K., received his Ph.D. in biochemistry from the University of Cambridge, U.K, and did post-doctoral research at Cambridge under Professor Sir Leszek Borysiewicz (ex Vice-Chancellor, University of Cambridge, Chair CancerUK).